52 related articles for article (PubMed ID: 20957480)
1. UGT1A1*1/*28 and *1/*6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer.
Sunakawa Y; Ichikawa W; Fujita K; Nagashima F; Ishida H; Yamashita K; Mizuno K; Miwa K; Kawara K; Akiyama Y; Araki K; Yamamoto W; Miya T; Narabayashi M; Ando Y; Hirose T; Saji S; Sasaki Y
Cancer Chemother Pharmacol; 2011 Aug; 68(2):279-84. PubMed ID: 20957480
[TBL] [Abstract][Full Text] [Related]
2. Relationship between UGT1A1*6/*28 polymorphisms and severe toxicities in Chinese patients with pancreatic or biliary tract cancer treated with irinotecan-containing regimens.
Yang C; Liu Y; Xi WQ; Zhou CF; Jiang JL; Ma T; Ye ZB; Zhang J; Zhu ZG
Drug Des Devel Ther; 2015; 9():3677-83. PubMed ID: 26229432
[TBL] [Abstract][Full Text] [Related]
3. Clinical Assessment of 5-Fluorouracil/Leucovorin, Nab-Paclitaxel, and Irinotecan (FOLFIRABRAX) in Untreated Patients with Gastrointestinal Cancer Using
Joshi SS; Catenacci DVT; Karrison TG; Peterson JD; Zalupski MM; Sehdev A; Wade J; Sadiq A; Picozzi VJ; Amico A; Marsh R; Kozloff MF; Polite BN; Kindler HL; Sharma MR
Clin Cancer Res; 2020 Jan; 26(1):18-24. PubMed ID: 31558477
[TBL] [Abstract][Full Text] [Related]
4. Relevance of CYP3A4*20, UGT1A1*37 and UGT1A1*28 variants in irinotecan-induced severe toxicity.
Riera P; Salazar J; Virgili AC; Tobeña M; Sebio A; Gallano P; Barnadas A; Páez D
Br J Clin Pharmacol; 2018 Jun; 84(6):1389-1392. PubMed ID: 29504153
[TBL] [Abstract][Full Text] [Related]
5. A Multicenter Clinical Phase II Study of FOLFOXIRI Plus Bevacizumab as First-line Therapy in Patients With Metastatic Colorectal Cancer: QUATTRO Study.
Oki E; Kato T; Bando H; Yoshino T; Muro K; Taniguchi H; Kagawa Y; Yamazaki K; Yamaguchi T; Tsuji A; Iwamoto S; Nakayama G; Emi Y; Touyama T; Nakamura M; Kotaka M; Sakisaka H; Yamanaka T; Kanazawa A
Clin Colorectal Cancer; 2018 Jun; 17(2):147-155. PubMed ID: 29530335
[TBL] [Abstract][Full Text] [Related]
6. UGT1A1 polymorphisms with irinotecan-induced toxicities and treatment outcome in Asians with Lung Cancer: a meta-analysis.
Chen X; Liu L; Guo Z; Liang W; He J; Huang L; Deng Q; Tang H; Pan H; Guo M; Liu Y; He Q; He J
Cancer Chemother Pharmacol; 2017 Jun; 79(6):1109-1117. PubMed ID: 28502040
[TBL] [Abstract][Full Text] [Related]
7. The association between UGT1A1 polymorphisms and treatment toxicities of liposomal irinotecan.
Su YY; Chiang NJ; Chang JS; Wang YW; Shen BN; Li YJ; Hwang DY; Shan YS; Chen LT
ESMO Open; 2023 Feb; 8(1):100746. PubMed ID: 36527823
[TBL] [Abstract][Full Text] [Related]
8. Association of UGT1A1*6, UGT1A1*28, or ABCC2 c.3972C>T genetic polymorphisms with irinotecan-induced toxicity in Asian cancer patients: Meta-analysis.
Atasilp C; Biswas M; Jinda P; Nuntharadthanaphong N; Rachanakul J; Hongkaew Y; Vanwong N; Saokaew S; Sukasem C
Clin Transl Sci; 2022 Jul; 15(7):1613-1633. PubMed ID: 35506159
[TBL] [Abstract][Full Text] [Related]
9. Adding Adjuvants to Fluoropyrimidine-based Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: An Option Worthy of Serious Consideration.
Wu F; Zhou C; Wu B; Zhang X; Wang K; Wang J; Xiao L; Wang G
J Cancer; 2021; 12(2):417-427. PubMed ID: 33391438
[TBL] [Abstract][Full Text] [Related]
10. Pharmacometabolomic prediction of individual differences of gastrointestinal toxicity complicating myelosuppression in rats induced by irinotecan.
Gao Y; Li W; Chen J; Wang X; Lv Y; Huang Y; Zhang Z; Xu F
Acta Pharm Sin B; 2019 Jan; 9(1):157-166. PubMed ID: 30766787
[TBL] [Abstract][Full Text] [Related]
11. Distribution of uridine diphosphate glucuronosyltransferase 1A polymorphisms and their role in irinotecan-induced toxicity in patients with cancer.
Wang Y; Yi C; Wang Y; Li H; Li B; Wang D; Du J; Liu L; Wang X
Oncol Lett; 2017 Nov; 14(5):5743-5752. PubMed ID: 29113203
[TBL] [Abstract][Full Text] [Related]
12. Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis.
Liu D; Li J; Gao J; Li Y; Yang R; Shen L
BMC Cancer; 2017 Jun; 17(1):437. PubMed ID: 28637434
[TBL] [Abstract][Full Text] [Related]
13. Molecular Genetics External Quality Assessment Pilot Scheme for Irinotecan-Related UGT1A1 Genotyping in China.
Yi L; Lin G; Zhang K; Wang L; Zhang R; Xie J; Li J
PLoS One; 2016; 11(1):e0148081. PubMed ID: 26820647
[TBL] [Abstract][Full Text] [Related]
14. Prospective analysis of UGT1A1 promoter polymorphism for irinotecan dose escalation in metastatic colorectal cancer patients treated with bevacizumab plus FOLFIRI as the first-line setting: study protocol for a randomized controlled trial.
Yeh YS; Tsai HL; Huang CW; Wang JH; Lin YW; Tang HC; Sung YC; Wu CC; Lu CY; Wang JY
Trials; 2016 Jan; 17():46. PubMed ID: 26811156
[TBL] [Abstract][Full Text] [Related]
15. Genetic polymorphisms in cytochrome P450 and clinical outcomes of FOLFIRI chemotherapy in patients with metastatic colorectal cancer.
Dong N; Meng F; Wu Y; Wang M; Cui Y; Zhang S
Tumour Biol; 2015 Sep; 36(10):7691-8. PubMed ID: 25934339
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of UGT1A1 gene polymorphisms on irinotecan-based regimens as the treatment in metastatic colorectal cancer.
Li M; Wang Z; Guo J; Liu J; Li C; Liu L; Shi H; Liu L; Li H; Xie C; Zhang X; Sun W; Fang S; Bi X
Onco Targets Ther; 2014; 7():1653-61. PubMed ID: 25285015
[TBL] [Abstract][Full Text] [Related]
17. Association between the low-dose irinotecan regimen-induced occurrence of grade 4 neutropenia and genetic variants of
Moriya H; Saito K; Helsby N; Sugino S; Yamakage M; Sawaguchi T; Takasaki M; Kato H; Kurosawa N
Oncol Lett; 2014 Jun; 7(6):2035-2040. PubMed ID: 24932285
[TBL] [Abstract][Full Text] [Related]
18. Associations between UGT1A1*6/*28 polymorphisms and irinotecan-induced severe toxicity in Chinese gastric or esophageal cancer patients.
Gao J; Zhou J; Li Y; Peng Z; Li Y; Wang X; Shen L
Med Oncol; 2013; 30(3):630. PubMed ID: 23783485
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetic study of deferasirox, an iron chelating agent.
Lee JW; Kang HJ; Choi JY; Kim NH; Jang MK; Yeo CW; Lee SS; Kim H; Park JD; Park KD; Shin HY; Shin JG; Ahn HS
PLoS One; 2013; 8(5):e64114. PubMed ID: 23737969
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]